A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Trial Details

NCT ID

NCT06992258

Phase

PHASE2

Sponsor

Criterium, Inc.

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Fruquintinib+ Lonsurf (trifluridine and tipiracil)
• Fruquintinib

Locations (sample)

• New Haven, Connecticut, United States|41.30815,-72.92816
• Miami Beach, Florida, United States|25.79065,-80.13005
• Orlando, Florida, United States|28.53834,-81.37924
• New Brunswick, New Jersey, United States|40.48622,-74.45182
• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Provision to sign and date the consent form
• Able to comply with all study procedures and be available for the duration of the study in the investigator's judgment
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
• Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.